Search Results

You are looking at 51 - 59 of 59 items for :

  • "heart transplantation" x
  • All content x
Clear All

–759. 17 Yardley M, Gullestad L, Nytrøen K. Importance of physical capacity and the effects of exercise in heart transplant recipients. World J Transplant. 2018; 8: 1–12. 18

Restricted access

–415. Chin, C., Chen, G., Sequeria, F., et al.: Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J. Heart Lung Transplant., 2011, 30 (2), 158

Open access
Orvosi Hetilap
Authors: Péter Apor, Máté Petrekanich, and Júlianna Számadó

variability after heart transplantation: 10-year follow-up. Transplantation, 2004, 78 , 1523–1531. Speijer G. Different evolutions in heart rate variability after heart transplantation

Open access

Przybylowski, P., Malyszko, J., Malyszko, J. S.: Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant. Proc., 2010, 42 , 1808–1811. Malyszko J. S

Open access

Szabó G, Bahrle S, Stumpf N, Sonnenberg K, Szabó E, Pacher P, Csont T, Schulz R, Dengler TJ, Liaudet L, Jagtap PG, Southan GJ, Vahl CF, Hagl S, Szabó C: Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ

Restricted access
Physiology International
Authors: K. Kalantar, Z. Farzaneh, M. Eshkevar Vakili, M.H. Karimi, M. Asadi, S. Khosropanah, and M. Doroudchi

atherosclerosis [ 4, 27–31 ]. CMV infection has been associated with accelerated heart transplant vasculopathy, cardiac allograft rejection and atherosclerosis [ 32, 33 ]. A recent report has shown an association between CVD mortality and CMV antibody titers [ 34

Restricted access

Malyszko , J. ( 2013 ): Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin . Transplant. Proc. 45 , 387 – 390 . 10.1016/j.transproceed.2012.02.040 Shimamori , T. , Noda

Restricted access

CDI, but more accurate studies of this phenomenon are necessary [ 12 ]. Other significant risk factors for CDI are immunosuppression, e.g., in transplant patients, especially heart transplants, as well as cystic fibrosis, vitamin D deficiency

Restricted access

The journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 32 707 713 . 119

Restricted access